Hosted on MSN18m
Boehringer seeks approval of lung disease drug after second Phase III success
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
News Medical on MSN3h
GUK1 enzyme plays crucial role in lung cancer metabolism and growth
Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, and it can shapeshift in unpredictable ways to evade treatment.
FierceBiotech14h
Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...
Peninsula biotech sheds 60% of its value as it pauses key clinical trial
A Peninsula biotech company focusing on a deadly lung-scarring disease lost more than half its stock value Monday after ...
BioSpace12h
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
SARS-CoV-2 infection linked to more rapid plaque growth in lesions
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with more rapid progression of coronary ...
The Lancet5h
Management and mechanisms of eosinophil action in asthma: mind the gap?
The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...